| Item Type | Name |
|
Concept
|
Combined Modality Therapy
|
|
Academic Article
|
Concomitant chemoradiotherapy as primary therapy for locoregionally advanced head and neck cancer.
|
|
Academic Article
|
Carboplatin plus vinorelbine with concomitant radiation therapy in advanced non-small cell lung cancer: a phase I study.
|
|
Academic Article
|
Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanced head and neck cancer.
|
|
Academic Article
|
Intensive concurrent chemoradiotherapy for head and neck cancer with 5-Fluorouracil- and hydroxyurea-based regimens: reversing a pattern of failure.
|
|
Academic Article
|
Induction chemotherapy followed by concomitant TFHX chemoradiotherapy with reduced dose radiation in advanced head and neck cancer.
|
|
Academic Article
|
Neck dissection in the combined-modality therapy of patients with locoregionally advanced head and neck cancer.
|
|
Academic Article
|
Twice-daily reirradiation for recurrent and second primary head-and-neck cancer with gemcitabine, paclitaxel, and 5-fluorouracil chemotherapy.
|
|
Academic Article
|
Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, gemcitabine, and twice-daily radiation in patients with poor-prognosis cancer of the head and neck.
|
|
Academic Article
|
Multicenter randomized Phase II study of paclitaxel (1-hour infusion), fluorouracil, hydroxyurea, and concomitant twice daily radiation with or without erythropoietin for advanced head and neck cancer.
|
|
Academic Article
|
Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinoma.
|
|
Academic Article
|
Therapeutic options for laryngeal cancer.
|
|
Academic Article
|
Phase I study of induction chemotherapy and concomitant chemoradiotherapy with irinotecan, carboplatin, and paclitaxel for stage III non-small cell lung cancer.
|
|
Academic Article
|
Intensity-modulated radiation therapy in advanced head and neck patients treated with intensive chemoradiotherapy: preliminary experience and future directions.
|
|
Academic Article
|
Phase I trial of tirapazamine, cisplatin, and concurrent accelerated boost reirradiation in patients with recurrent head and neck cancer.
|
|
Academic Article
|
Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer.
|
|
Academic Article
|
Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer.
|
|
Academic Article
|
Concurrent chemoradiotherapy for head and neck cancer.
|
|
Academic Article
|
Phase I study of concomitant chemoradiotherapy with irinotecan, 5-FU, and hydroxyurea for patients with advanced and/or recurrent head and neck cancer.
|
|
Academic Article
|
Characteristics associated with swallowing changes after concurrent chemotherapy and radiotherapy in patients with head and neck cancer.
|
|
Academic Article
|
Chemoradiation for patients with advanced oral cavity cancer.
|
|
Academic Article
|
Chemoreirradiation for recurrent salivary gland malignancies.
|
|
Academic Article
|
Epidermal growth factor receptor inhibitor gefitinib added to chemoradiotherapy in locally advanced head and neck cancer.
|
|
Academic Article
|
A randomized phase II study of 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy compared with bevacizumab plus 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy for intermediate-stage and T4N0-1 head and neck cancers.
|
|
Academic Article
|
Phase II trial of pemetrexed-based induction chemotherapy followed by concomitant chemoradiotherapy in previously irradiated patients with squamous cell carcinoma of the head and neck.
|
|
Academic Article
|
Concurrent chemotherapy and intensity-modulated radiotherapy for organ preservation of locoregionally advanced oral cavity cancer.
|
|
Academic Article
|
Efficacy and safety of treating T4 oral cavity tumors with primary chemoradiotherapy.
|
|
Academic Article
|
Long-term outcome of a phase II study of docetaxel-based multimodality chemoradiotherapy for locally advanced carcinoma of the esophagus or gastroesophageal junction.
|
|
Academic Article
|
A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer.
|
|
Academic Article
|
Everolimus exhibits efficacy as a radiosensitizer in a model of non-small cell lung cancer.
|
|
Academic Article
|
Trends and perspectives in multimodality therapy of locoregionally advanced non-small cell lung cancer.
|
|
Academic Article
|
Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: cancer and leukemia group B study 9431.
|
|
Academic Article
|
Induction chemotherapy and radiotherapy in locally advanced non-small cell lung cancer.
|
|
Academic Article
|
Induction paclitaxel/carboplatin followed by concurrent chemoradiation therapy for unresectable stage III non-small-cell lung cancer: a limited-access study--CALGB 9534.
|
|
Academic Article
|
The chemoradiation paradigm in head and neck cancer.
|
|
Academic Article
|
The concurrent chemoradiation paradigm--general principles.
|
|
Academic Article
|
Chemoradiotherapy for locally advanced head and neck cancer.
|
|
Academic Article
|
Docetaxel and exisulind in previously treated non-small cell lung cancer (NSCLC) patients: a multicenter, phase II clinical trial.
|
|
Academic Article
|
Current treatments and promising investigations in a multidisciplinary setting.
|
|
Academic Article
|
A phase III study of surgical resection and paclitaxel/carboplatin chemotherapy with or without adjuvant radiation therapy for resected stage III non-small-cell lung cancer: Cancer and Leukemia Group B 9734.
|
|
Academic Article
|
Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B.
|
|
Academic Article
|
Phase II trial of paclitaxel-topotecan-etoposide followed by consolidation chemoradiotherapy for limited-stage small cell lung cancer: CALGB 30002.
|
|
Academic Article
|
Concurrent chemotherapy and re-irradiation for locoregionally recurrent head and neck cancer.
|
|
Academic Article
|
Curative treatment for advanced head and neck cancer in the community: has the time come?
|
|
Academic Article
|
Treatment outcomes of different prognostic groups of patients on cancer and leukemia group B trial 39801: induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for unresectable stage III non-small cell lung cancer.
|
|
Academic Article
|
Combining radiotherapy with systemic therapies.
|
|
Academic Article
|
Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105.
|
|
Academic Article
|
Chemoradiotherapy and gefitinib in stage III non-small cell lung cancer with epidermal growth factor receptor and KRAS mutation analysis: cancer and leukemia group B (CALEB) 30106, a CALGB-stratified phase II trial.
|
|
Academic Article
|
Induction chemotherapy: to use or not to use? That is the question.
|
|
Academic Article
|
Cooperative group portfolio in locally advanced non-small-cell lung cancer: are we making progress?
|
|
Academic Article
|
Randomized phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small-cell lung cancer: Cancer and Leukemia Group B trial 30407.
|
|
Academic Article
|
Seeking improved outcome in the curative treatment of non-small-cell lung cancer.
|
|
Academic Article
|
Locally advanced non-small cell lung cancer: the past, present, and future.
|
|
Academic Article
|
PROCLAIM: A phase III study of pemetrexed, cisplatin, and radiation therapy followed by consolidation pemetrexed versus etoposide, cisplatin, and radiation therapy followed by consolidation cytotoxic chemotherapy of choice in locally advanced stage III non-small-cell lung cancer of other than predominantly squamous cell histology.
|
|
Academic Article
|
Induction chemotherapy followed by concomitant chemoradiotherapy for non-small cell lung cancer.
|
|
Academic Article
|
Targeted therapies for stage III non-small cell lung cancer: integration in the combined modality setting.
|
|
Academic Article
|
Induction or consolidation systemic therapy in the multimodality treatment of unresectable locally advanced non-small cell lung cancer.
|
|
Academic Article
|
Cetuximab in cancers of the lung and head & neck.
|
|
Academic Article
|
Concurrent chemoradiotherapy for unresectable stage III non-small cell lung cancer.
|
|
Academic Article
|
Interruptions of once-daily thoracic radiotherapy do not correlate with outcomes in limited stage small cell lung cancer: analysis of CALGB phase III trial 9235.
|
|
Academic Article
|
Effects of vascular endothelial growth factor signaling inhibition on human erythropoiesis.
|
|
Academic Article
|
Race and competing mortality in advanced head and neck cancer.
|
|
Academic Article
|
Toxicity Related to Radiotherapy Dose and Targeting Strategy: A Pooled Analysis of Cooperative Group Trials of Combined Modality Therapy for Locally Advanced Non-Small Cell Lung Cancer.
|
|
Academic Article
|
Exploring Radiotherapy Targeting Strategy and Dose: A Pooled Analysis of Cooperative Group Trials of Combined Modality Therapy for Stage III NSCLC.
|
|
Academic Article
|
Short Communication: Interim toxicity analysis for patients with limited stage small cell lung cancer (LSCLC) treated on CALGB 30610 (Alliance) / RTOG 0538.
|
|
Academic Article
|
Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors.
|